ReviewDiabetology international2025
Evolving incretin-based therapies in Japan: optimizing treatment strategies for diverse clinical and socioeconomical profiles in type 2 diabetes.
Review in Diabetology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Beyond weight loss: Preserving muscle health in the incretin era.Journal of diabetes investigation · 2026Article
- Treatment Selection Patterns and Associated Outcomes for Biguanides and SGLT2 Inhibitors in Type 2 Diabetes: A Retrospective Database Study in Japan.Drugs - real world outcomes · 2026Article
- Recent advances in incretin biology and therapeutics: From glucose-dependent insulinotropic polypeptide reappraisal to next-generation agonists.Journal of diabetes investigation · 2026Review
- Endogenous GIP signaling is indispensable for DPP-4 inhibitor-mediated metabolic control in mice.Journal of diabetes investigation · 2026Article
- Association between daily dose of dipeptidyl peptidase-4 inhibitors and change in glycated hemoglobin in patients with type 2 diabetes: interpretation of mixed-effects machine-learning models using electronic medical records.BMC pharmacology & toxicology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The management of type 2 diabetes has evolved significantly with the advent of incretin-based therapies, particularly dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists. In Japan, where over 70% of individuals with diabetes are aged 65 or older and often exhibit a non-obese phenotype with impaired insulin secretion, dipeptidyl peptidase-4 inhibitors remain a cornerstone therapy due to their ability to enhance insulin secretion without increasing hypoglycemia risk. Meanwhile, in younger adults with obesity, glucagon-like peptide-1 receptor agonists play a crucial role by improving glycaemia, promoting weight loss, and offering cardiovascular and renal protection. A major breakthrough in 2023 was the introduction of glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist tirzepatide, which activates both receptors and has shown superior glucose-lowering and weight-reducing effects in both clinical trials and real-world Japanese settings. However, incretin-based therapies are frequently associated with gastrointestinal side effects, and concerns remain regarding their potential impact on pancreatic and biliary diseases as well as frailty and sarcopenia in older adults. In addition, inappropriate discontinuation of insulin following incretin therapy initiation has led to severe outcomes, emphasizing the need for careful clinical decision-making beyond trial data. Emerging incretin-related therapies are under investigation for obesity and metabolic disorders including type 2 diabetes. While these agents hold promise for enhanced metabolic, weight, and cardiorenal benefits, their long-term safety and applicability require further study. To optimize therapeutic strategies, adherence to evidence-based guidelines, such as the "Recommendations for the Safe Use of Incretin-Related Agents, Second Edition" by the Japanese Diabetes Society, is essential.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.